Cargando…
Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study
BACKGROUND: Intravesical bacillus Calmette-Guerin (BCG) therapy is the treatment of choice for patients with T1 or high-grade superficial bladder cancer or those with carcinoma in situ after transurethral resection. A personal history of tuberculosis infection has been viewed as a relative contraind...
Autores principales: | Hsu, Che-Wei, Chiu, Yi-Chun, Hu, Hsiao-Yun, Fan, Yu-Hua, Hong, Shih-Chi, Cheng, Wei-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346498/ https://www.ncbi.nlm.nih.gov/pubmed/32641099 http://dx.doi.org/10.1186/s12894-020-00642-1 |
Ejemplares similares
-
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007) -
Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019) -
Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016) -
Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020) -
Tuberculosis epididymo-orchitis following intravesical bacillus Calmette-Guérin immunotherapy
por: Rezvani, Sean, et al.
Publicado: (2019)